These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36200348)

  • 1. Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure.
    Shaw JR; Li N; Nixon J; Moffat KA; Spyropoulos AC; Schulman S; Douketis JD
    J Thromb Haemost; 2022 Dec; 20(12):2953-2963. PubMed ID: 36200348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
    Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
    J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban.
    Volod O; Rollins-Raval M; Goodwin AJ; Higgins RA; Long T; Chandler WL; Harris NS; Pham HP; Isom JA; Moser K; Olson JD; Smock KJ; VanSandt A; Wool G; Chen D
    Arch Pathol Lab Med; 2022 Jan; 146(2):145-153. PubMed ID: 34133726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
    Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.
    Tripodi A; Chantarangkul V; Legnani C; Testa S; Tosetto A
    J Thromb Haemost; 2018 Mar; 16(3):565-570. PubMed ID: 29322630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
    J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
    Ząbczyk M; Kopytek M; Natorska J; Undas A
    Clin Chem Lab Med; 2019 Aug; 57(9):1374-1381. PubMed ID: 30763261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PT, aPTT, TT and the hemostatic safety threshold of dabigatran and rivaroxaban.
    Ibrahim F; Calmette L; Layka A; Horellou MH; Mazoyer É; Gouin-Thibault I; Flaujac C
    Ann Biol Clin (Paris); 2016 Aug; 74(4):457-64. PubMed ID: 27492699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy: An Affordable and Reliable Strategy?
    Silva VM; Scanavacca M; Darrieux F; Cavalheiro C; Strunz CC
    Clin Appl Thromb Hemost; 2019; 25():1076029619835053. PubMed ID: 30907118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators.
    Lim MS; Chapman K; Swanepoel P; Enjeti AK
    Pathology; 2016 Dec; 48(7):712-719. PubMed ID: 27780603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.
    Mahamad S; Chaudhry H; Nisenbaum R; McFarlan A; Rizoli S; Ackery A; Sholzberg M
    J Thromb Thrombolysis; 2019 Feb; 47(2):272-279. PubMed ID: 30506352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
    Antovic A; Norberg EM; Berndtsson M; Rasmuson A; Malmström RE; Skeppholm M; Antovic J
    Thromb Haemost; 2017 Aug; 117(9):1700-1704. PubMed ID: 28640321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of coagulation indices for direct oral anticoagulant concentration.
    Zhang H; Liu Z; Mu G; Wang Z; Zhou S; Xie Q; Ma L; Wang Z; Hu K; Gong Y; Jiang J; Xiang Q; Cui Y
    Thromb Res; 2020 Nov; 195():171-179. PubMed ID: 32711233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis.
    Liu Z; Zhang H; Xie Q; Mu G; Zhou S; Wang Z; Wang Z; Jiang J; Xiang Q; Cui Y
    Clin Ther; 2020 Oct; 42(10):2066-2081.e9. PubMed ID: 32900534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
    Cuker A; Siegal DM; Crowther MA; Garcia DA
    J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance Characteristics of DOAC-Remove for Neutralization of the Effects of Apixaban and Rivaroxaban in Lupus Anticoagulant Assays.
    Skaugen JM; Sayre C; Hassett AC; Chibisov I; Bontempo F; Meyer MP; Seheult JN
    Am J Clin Pathol; 2022 Mar; 157(3):457-469. PubMed ID: 34698336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.
    Letertre LR; Gudmundsdottir BR; Francis CW; Gosselin RC; Skeppholm M; Malmstrom RE; Moll S; Hawes E; Francart S; Onundarson PT
    J Thromb Haemost; 2016 May; 14(5):1043-53. PubMed ID: 26924677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.